‘Obesity therapy mkt set to evolve rapidly’
Danish firm Novo Nordisk expects India’s obesity therapy market to evolve rapidly, saying its recent Wegovy (injectable semaglutide) price cut could lift patient uptake five-to-seven-fold, echoing its insulin experience. This comes even as lower-priced generics loom, with a rival drugmaker, Eli Lilly & Co, also eyeing a share of one of the fastest-growing therapy segments.“Our…
